BY SHARON KABBES CHRISMAN: By the time diabetes upended our lives, our parental trio had been raising two daughters in two homes, for six years. We three are very different people. There’s me, mom—the artistic, empathetic, medically-intuitive, communicator; stepdad—the psych-degreed, level-headed, listening, quiet guy; and Dad—the sees-things-in-black-and-white, wicked-smart engineer who can fix most every single little (or big) broken thing you put in front of him, except for his daughter’s busted pancreas.
Our dynamics are anything but normal. By the time I met and married my girls’ dad, I had already been best friends with their now stepdad for half my life. We folded him into our daily lives and both girls entered the world with him as their “uncle.” (read more)
BY DUBLIN CITY UNIVERSITY: Researchers at Dublin City University and their project partners in the EU FP7 funded DEXLIFE project have found fresh evidence to explain the processes that occur in the body’s cells leading to the onset of type2 diabetes.
To date, the molecular mechanisms, underpinning, the development of type2 diabetes is not completely understood.
This new finding is important as it demonstrates what happens at a cellular level and how diabetes and insulin resistance occur. (read more)
BY FDA: The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product (submitted through the agency’s 505(b)(2) pathway).
According to the Centers for Disease Control and Prevention, more than 30 million people in the U.S. have diabetes, a chronic disease that affects how the body turns food into energy and the body’s production of natural insulin. Over time, diabetes increases the risk of serious health complications, including heart disease, blindness, and nerve and kidney damage. Improvement in blood sugar control through treatment with insulin, a common treatment, can reduce the risk of some of these long-term complications. (read more)
BY VANESSA CACERES: Insulin injections are a not-so-fun part of life for people with Type 1 diabetes and some with Type 2 diabetes. If there was an alternative available, like inhaled insulin, could it make living with diabetes easier?
That’s one of the ideas behind Afrezza, an insulin inhalation powder that was approved by the U.S. Food and Drug Administration in 2014.
Inhaled insulin works faster than injected insulin because it reaches the lung tissue immediately upon inhalation, says Dr. David Klonoff, medical director of the Diabetes Research Institute at the Mills-Peninsula Medical Center in San Mateo, California. “From there it can diffuse into the bloodstream faster than an insulin molecule injected into the skin,” he explains. That means the medication takes effect faster than injected insulin. In fact, its first measurable effect starts in about 12 minutes, and it has a peak effect in 35 to 45 minutes, according to information from the company website. It stops working in about 1.5 to 3 hours, depending on how much you’ve used. (read more)
BY MALIA HURST: As I gathered my notes and thoughts about the potential of diabetes technology in 2018, I kept coming back to the running list of caveats and elephants in the room. Access and affordability have been headline-generating conversations across the diabetes community this year. On one hand, it feels a little weird to talk about crazy-advanced technology that will hopefully make its way to the diabetes community next year while we’re still trying to figure out why live-sustaining medication costs as much as it does. If you are struggling to afford insulin, do you have room to get excited about automated insulin delivery?
But, innovation is important. (read more)